ArticleBMJ open respiratory research2026
Respiratory syncytial virus-induced SIGLEC1 upregulation inhibits macrophage autophagy and facilitates inflammatory mediator secretion.
Article in BMJ open respiratory research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundRespiratory syncytial virus (RSV) is a leading culprit behind respiratory infections in infants. As a cornerstone of the immune defence, macrophages are instrumental in warding off invading pathogens. This study examines the molecular pathways through which RSV modulates the immune functions of macrophages during infection.
methodsTHP-1-derived macrophages were infected with RSV, and the infection was monitored using fluorescence microscopy. The viability of infected macrophages was measured using CCK-8, and SIGLEC1 expression was analysed by RT-qPCR and western blot (WB). Gene set enrichment analysis was performed to identify pathways associated with SIGLEC1 enrichment. SIGLEC1-knockdown macrophages were developed, and autophagy levels in these cells following RSV infection were examined using WB, immunofluorescence and monodansylcadaverine staining. The influence of RSV infection on macrophage phenotype and inflammatory responses was assessed through morphological observation, flow cytometry, ELISA and nitric oxide synthase expression analysis.
resultsFollowing RSV infection, macrophage activity was significantly repressed, and SIGLEC1 expression was markedly upregulated. This upregulation of SIGLEC1 effectively suppressed the autophagy process in macrophages, as indicated by decreased levels of ATG5 and LC3II, and reduced autophagosome formation. RSV infection also drove macrophages towards the M1 phenotype, which was accompanied by increased secretion of proinflammatory cytokines. Importantly, these effects were reversible through SIGLEC1 knockdown or treatment with an autophagy activator, which restored autophagy levels and curbed the release of inflammatory mediators.
conclusionBy exposing how RSV exploits SIGLEC1 to inhibit macrophage autophagy, reinforce M1 polarisation and increase cytokine secretion, this study lays vital groundwork for new treatments targeting this viral scourge.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.